Larson Financial Group’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Larson Financial Group’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$416	Buy	+14	New	+$406	﹤0.01%	3346

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Larson Financial Group's IDNA Position: Q1 2026 in Review

Larson Financial Group opened a new position in iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2026: 14 shares worth $416. The stake represents ﹤0.01% of the portfolio and ranks #3346 among its holdings.

60 funds tracked by Wall St. Rank hold IDNA as of Q1 2026.

Larson Financial Group held 14 shares of iShares Genomics Immunology and Healthcare ETF worth $416 as of Q1 2026.
iShares Genomics Immunology and Healthcare ETF was a new Larson Financial Group position in Q1 2026.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3346 holding.
60 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.